The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

Valneva (VALN) stock gained as its chikungunya vaccine receives marketing authorization in the U.K., expanding the single-dose shot's global reach. Read more here.

Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...

Shares of Valneva (VALN), a specialty vaccine company closed up over $1.00 per share or almost 19% to close the regular session at $6.67 per ...

French biotech Valneva has secured marketing approval in the UK for its chikungunya vaccine, Ixchiq (chikungunya vaccine), ...

Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...